Cita APA

González-Sánchez, E., Muñoz Callejas, A., Gomez-Román, J., San Antonio, E., Marengo, A., Tsapis, N., . . . Urzainqui, A. (2022). Targeted nanotherapy with everolimus reduces inflammation and fibrosis in scleroderma-related interstitial lung disease developed by PSGL-1 deficient mice.

Citación estilo Chicago

González-Sánchez, Elena, et al. Targeted Nanotherapy With Everolimus Reduces Inflammation and Fibrosis in Scleroderma-related Interstitial Lung Disease Developed By PSGL-1 Deficient Mice. 2022.

Cita MLA

González-Sánchez, Elena, et al. Targeted Nanotherapy With Everolimus Reduces Inflammation and Fibrosis in Scleroderma-related Interstitial Lung Disease Developed By PSGL-1 Deficient Mice. 2022.